Patents by Inventor Ryan Koning

Ryan Koning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIFFERENTIATION OF STEM CELLS IN SUSPENSION CULTURE
    Publication number: 20260028588
    Abstract: Provided are xenogenic-free methods and compositions for generating hematopoietic progenitors and natural killer (NK) cells in 3D suspension culture.
    Type: Application
    Filed: July 27, 2023
    Publication date: January 29, 2026
    Applicant: Umoja Biopharma, Inc.
    Inventors: Teisha J. ROWLAND, Cassidy FRIEDMAN, Ashley M. YINGST, Samantha O'HARA, Dillon JARRELL, David T. VEREIDE, Ryan KONING
  • ENGINEERED STEM CELLS AND USES THEREOF
    Publication number: 20250367290
    Abstract: Provided are compositions and methods for a cell population comprising engineered stem cells comprising a synthetic cytokine receptor for a non-physiological ligand. The non-physiological ligand activates the synthetic cytokine receptor in the engineered stem cells to induce differentiation of the stem cells and, expansion and/or activation of resulting cytotoxic innate lymphoid cells.
    Type: Application
    Filed: June 10, 2023
    Publication date: December 4, 2025
    Applicant: Umoja Bioharma, Inc.
    Inventors: Samantha O'HARA, David T. VEREIDE, Ryan LARSON, Andrew SCHARENBERG, Ashley YINGST, Dillon JARRELL, Ryan KONING, Teisha ROWLAND
  • CYTOTOXIC INNATE LYMPHOID CELL AND USES THEREOF
    Publication number: 20250041415
    Abstract: Provided are compositions and methods for a cell population comprising engineered cytotoxic innate lymphoid cells engineered for controlled expansion and/or activity, the engineered cytotoxic innate lymphoid cells comprising a synthetic cytokine receptor for a non-physiological ligand. The cytokine receptor may comprise a synthetic gamma chain polypeptide as a first dimerization domain, a first transmembrane domain, and an interleukin-2 receptor subunit gamma (IL-2RG) intracellular domain and a synthetic beta chain polypeptide as a second dimerization domain, a second transmembrane domain, and an intracellular domain selected from an interleukin-2 receptor subunit beta (IL-2RB) intracellular domain, an interleukin-7 receptor subunit beta (IL-7RB) intracellular domain, and/or an interleukin-21 receptor subunit beta (IL-21RB) intracellular domain.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 6, 2025
    Applicant: Umoja Biopharma, Inc.
    Inventors: Samantha O'HARA, Andrew SCHARENBERG, Ryan CRISMAN, Christopher NICOLAI, Teisha ROWLAND, Ryan LARSON, Ryan KONING, Christopher GARBE, David VERIEDE, Byoung RYU
  • ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN
    Publication number: 20240226160
    Abstract: Activity-inducible fusion proteins whose activity is post-translationally regulated utilizing a hsp90 binding domain and a drug molecule are described. In the absence of the drug molecule, the activity-inducible fusion proteins are inactivated but can be activated by a relevant physiological parameter in the presence of the drug molecule. Examples of the activity-inducible fusion proteins include chimeric antigen receptors (CAR) wherein the relevant physiological parameter is antigen binding.
    Type: Application
    Filed: February 11, 2022
    Publication date: July 11, 2024
    Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    Inventors: Ryan Koning, Adam Johnson, Chris Saxby, Michael C. Jensen, Ian Blumenthal, Aquene Reid
  • ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN
    Publication number: 20240131072
    Abstract: Activity-inducible fusion proteins whose activity is post-translationally regulated utilizing a hsp90 binding domain and a drug molecule are described. In the absence of the drug molecule, the activity-inducible fusion proteins are inactivated but can be activated by a relevant physiological parameter in the presence of the drug molecule. Examples of the activity-inducible fusion proteins include chimeric antigen receptors (CAR) wherein the relevant physiological parameter is antigen binding.
    Type: Application
    Filed: February 11, 2022
    Publication date: April 25, 2024
    Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    Inventors: Ryan Koning, Adam Johnson, Chris Saxby, Michael C. Jensen, Ian Blumenthal, Aquene Reid